In this work, two different SNPs (rs1058808 HER2Ala1170Pro and rs2070096 BARD1Thr351=) are proposed as potential biomarkers of a good response to anti-HER2 treatment in patients with early HER2-positive breast cancer. Here, ERBB2 is linked to breast cancer.